scholarly journals Occurrence of Cardiovascular Complications Associated with SARS-CoV-2 Infection: A Systematic Review

2021 ◽  
pp. 8-20
Author(s):  
Daniele Melo Sardinha ◽  
Karla Valéria Batista Lima ◽  
Thalyta Mariany Rêgo Lopes Ueno ◽  
Yan Correa Rodrigues ◽  
Juliana Conceição Dias Garcez ◽  
...  
Keyword(s):  
Risk Factors ◽  
Heart Failure ◽  
Systematic Review ◽  
Cardiac Injury ◽  
Severe Pneumonia ◽  
Cardiovascular Complications ◽  
World Health ◽  
The World ◽  
Health Organization ◽  
Cardiopulmonary System

Cardiovascular Diseases represent the main cause of death in the world, and are associated with risk factors that cause serious complications in cases of infections, such as those of the respiratory tract. In March 2020 the World Health Organization declared a pandemic for SARS-CoV-2, a new coronavirus causing severe pneumonia, which emerged in December 2019 in Wuhan, China. The objective is to investigate the occurrence of cardiovascular complications associated with SARS-CoV-2 infection. It is a systematic review, quantitative, in the databases, PubMed and Science direct, including primary studies with hospitalized patients confirmed for COVID-19 and who presented cardiovascular complications, the form used tools for evaluation of quality and evidence, following the PRISMA recommendations. Results: 12 studies were included. The occurrence of cardiovascular complications was: 27.35% of the sample of 3,316 patients. Types: Acute cardiac injury 17.09%; Thromboembolism 4.73%; Heart failure 3.43%; Arrhythmias 1.77%; stroke 0.33%. Mean age 61 years. Conclusions: This study showed that there are several cardiovascular complications associated with SARS-CoV-2, that the main one is acute cardiac injury, which causes several instabilities in the cardiopulmonary system, and that it is associated with mortality.

scholarly journals Occurrence of cardiovascular complications associated with SARS-CoV-2 infection: a systematic review

2020 ◽  
Author(s):  
Daniele Melo Sardinha ◽  
Karla VB Lima ◽  
Thalyta MRL Ueno ◽  
Yan Correa Rodrigues ◽  
Juliana CD Garcez ◽  
...  
Keyword(s):  
Risk Factors ◽  
Heart Failure ◽  
Systematic Review ◽  
Cardiac Injury ◽  
Severe Pneumonia ◽  
Cardiovascular Complications ◽  
World Health ◽  
The World ◽  
Health Organization ◽  
Cardiopulmonary System

AbstractCardiovascular Diseases represent the main cause of death in the world, and are associated with risk factors that cause serious complications in cases of infections, such as those of the respiratory tract. In March 2020 the World Health Organization declared a pandemic for SARS-CoV-2, a new coronavirus causing severe pneumonia, which emerged in December 2019 in Wuhan, China. The objective is to investigate the occurrence of cardiovascular complications associated with SARS-CoV-2 infection. It is a systematic review, quantitative, in the databases, PubMed and Science direct, including primary studies with hospitalized patients confirmed for COVID-19 and who presented cardiovascular complications, the form used tools for evaluation of quality and evidence, following the PRISMA recommendations. Results: 12 studies were included. The occurrence of cardiovascular complications was: 27.35% of the sample of 3,316 patients. Types: Acute cardiac injury 17.09%; Thromboembolism 4.73%; Heart failure 3.43%; Arrhythmias 1.77%; stroke 0.33%. Mean age 61 years. Conclusions: This study showed that there are several cardiovascular complications associated with SARS-CoV-2, that the main one is acute cardiac injury, which causes several instabilities in the cardiopulmonary system, and that it is associated with mortality.

scholarly journals COVID-19 and Standardized Vaccines Development: A Brief Review

2021 ◽  
Vol 23 (05) ◽  
pp. 325-343
Author(s):  
Nisha Kaushik ◽  
◽  
Arti R. Thakkar ◽  
K. Bangarurajan ◽  
◽  
...  
Keyword(s):  
Viral Vectors ◽  
Cardiac Injury ◽  
Severe Pneumonia ◽  
The Body ◽  
World Health ◽  
Atypical Form ◽  
Area Of Interest ◽  
The World ◽  
Attenuated Viruses ◽  
Health Organization

The severe acute respiratory syndrome coronavirus disease (COVID-19) pandemic brings a global emergency affecting all civilizations. After the initial spread from Wuhan City atypical form of pneumonia to other areas of the world led the world health organization to look after it as a pandemic situation. The clinical coronavirus now spread all over the globe and brutally affected almost all countries including community transmission. The current capital of coronavirus cases in the US, trailed by India and Brazil, respectively. The most common symptoms were mild to moderate respiratory discomfort. Lung was the main targeting organ for COVID-19 infection resulting in severe pneumonia. Furthermore, severe acute respiratory distress syndrome (ARDS), acute cardiac injury, along with pathological features such as RNAaemia with shared ground-glass opacities that may be a cause for death in patients. The surface glycoproteins may be responsible for this garnishing of the virus belonging to the Coronaviridae family. Vaccines work to enhance the immune system of the body by training and making it ready to fight a specific pathogenic agent. At present there over 50 COVID-19 vaccine candidates are in trials, some of which are now ready to deliver via emergency use authorization (EUA). The vast majority of viral vaccines currently licensed for humans can be categorized as inactivated or live-attenuated viruses and protein-based subunit vaccines. Hence, we hereby review the significance of certain genotypic vaccines that are currently subjected for development such as non-replicating viral vectors, mRNA vaccine, self-amplifying mRNA vaccine, DNA vaccine, whole-virus inactivated vaccine, and a subunit vaccine. The current review also explores the mode of pathogenesis and invasion of COVID-19 virus to host cell that would be well-comprised data for future studies in the concerned area of interest.

Prevalence of and factors associated with insufficient physical activity among adolescents: evidence from a nationwide survey in Bangladesh

2021 ◽  
pp. 1-14
Author(s):  
Md Mokbul Hossain ◽  
Fahmida Akter ◽  
Abu Abdullah Mohammad Hanif ◽  
Md Showkat Ali Khan ◽  
Abu Ahmed Shamim ◽  
...  
Keyword(s):  
Physical Activity ◽  
Risk Factors ◽  
World Health Organization ◽  
Adolescent Girls ◽  
World Health ◽  
Factors Associated ◽  
Adolescent Girls And Boys ◽  
The World ◽  
Insufficient Physical Activity ◽  
Health Organization

Abstract The World Health Organization set a target of a 15% relative reduction in the prevalence of insufficient physical activity (IPA) by 2025 among adolescents and adults globally. In Bangladesh, there are no national estimates of the prevalence of IPA among adolescents. The aim of this study was to estimate the prevalence of and risk factors associated with IPA among adolescent girls and boys. Data for 4865 adolescent girls and 4907 adolescent boys, collected as a part of a National Nutrition Surveillance in 2018–19, were analysed for this study. A modified version of the Global Physical Activity Questionnaire (GPAQ) was used to collect physical activity data. The World Health Organization recommended cut-off points were used to estimate the prevalence of IPA. Bivariate and multivariable logistic regression was performed to identify factors associated with IPA. Prevalences of IPA among adolescent girls and boys were 50.3% and 29.0%, respectively, and the prevalence was significantly higher among early adolescents (10–14 years) than late adolescents (15–19 years) among both boys and girls. The IPA prevalence was highest among adolescents living in non-slum urban areas (girls: 77.7%; boys: 64.1%). For both boys and girls, younger age, non-slum urban residence, higher paternal education and increased television viewing time were significantly associated with IPA. Additionally, residing in slums was significantly associated with IPA only among the boys. Higher maternal education was associated with IPA only among the girls. This study identified several modifiable risk factors associated with IPA among adolescent boys and girls in Bangladesh. These factors should be addressed through comprehensive public health interventions to promote physical activity among adolescent girls and boys.

The Association Between Racism and Suicidality Among Young Minority Groups: A Systematic Review

2021 ◽  
pp. 104365962110469
Author(s):  
Giorgia Rudes ◽  
Claudia Fantuzzi
Keyword(s):  
Systematic Review ◽  
Health Care Professionals ◽  
Suicide Risk ◽  
Minority Groups ◽  
World Health ◽  
Physical And Mental Health ◽  
Dominant Culture ◽  
The World ◽  
Health Organization ◽  
The Relationship

Introduction: The World Health Organization states that suicide is the second leading cause of death among youngs, and racism has been proven to have detrimental effects on both physical and mental health. These two plagues represent a public health priority, especially for susceptible minorities. Method: This systematic review analyzed 23 studies from multiple database searches, to understand the relationship between racism and suicidality in young minority groups. Results: The review demonstrated the correlation between racism and suicidality with the consequent development of mental disorders. There is strong evidence that the main suicide risk factor is acculturation, interpreted as the assimilation of the dominant culture with the loss of values from one’s cultural background. Discussion: Health care professionals should not underestimate the risk of suicidality associated with racism. Prevention is crucial and it should be implemented from a young age, in schools, through a joint intervention with children and their families, aiming toward integration without acculturation.

scholarly journals E-HEALTH NURSING VIRTUAL REALITY TREND PADA PASIEN SKIZOFRENIA GUNA MENINGKATKAN KESEHATAN MENTAL: SYSTEMATIC REVIEW

2021 ◽  
pp. 172-180
Author(s):  
Fitrio Deviantony ◽  
Grysha Viofananda ◽  
Nurul Hidayah ◽  
Nadhifa Eriyanti
Keyword(s):  
Mental Health ◽  
Systematic Review ◽  
Virtual Reality ◽  
World Health Organization ◽  
World Health ◽  
Reality Therapy ◽  
Virtual Reality Therapy ◽  
The World ◽  
Health Nursing ◽  
Health Organization

permasalahan serius di dunia dan Indonesia. Data dari World Health Organization sekitar 21 juta orang mengalami skizofrenia. Prevalensi skizofrenia di Indonesia mengalami peningkatan proporsi per 1000 penduduk (1,7%) pada tahun 2013 menjadi (7%) pada tahun 2018. Faktanya terapi keperawatan untuk halusinasi belum optimal sedangkan teknologi terus berkembang seperti Virtual Reality (VR). VR mampu menurunkan gejala pada skizofrenia dengan kemampuan membuat perilaku interaktif dan tersimpan dalam otak agar tidak menimbulkan halusinasi. Teknologi ini digunakan untuk mengetahui manfaat E-Health Nursing VR sebagai terapi halusinasi pada pasien skizofrenia. Metode penelitian menggunakan systematic review dari 5 database yaitu Nature, Frontiers, BMC, Science Direct, NEJM sehingga didapat total 55 literatur. Mayoritas 63% mengulas terapi VR untuk mengurangi halusinasi pada skizofrenia. Perkembangan manfaat VR diverifikasi dalam beberapa pengobatan: skizofrenia, PTSD, kecemasan, akrofobia, ganguan citra tubuh, claustrophobia, dan lain-lain. Beberapa studi skizofrenia menyatakan terapi VR sangat efektif menangani delusi, halusinasi, gejala kepribadian skizoid. VR juga berguna dalam rehabilitas kognitif pada orang dewasa atau anak-anak autis dalam keterampilan dan kemandirian. Kesimpulan penelitian ini adalah VR terbukti efektif sebagai terapi kesehatan jiwa di masa mendatang. Disisi lain terdapat terapi psikologis pilihan seperti terapi perilaku kognitif, dan psikoterapi interpersonal. Oleh karenanya diperlukan kombinasi terapi VR dengan terapi komplementer tersebut dalam mengurangi halusinasi pada skizofrenia.   Mental health become a severe problem in the world and Indonesia. Data from the World Health Organization (WHO, 2016) estimated that 21 million people have schizophrenia. The prevalence of schizophrenia in Indonesia has increased proportion per 1000 population (1,7%) in 2013 to (7%) in 2018. In fact of nursing, therapy for hallucination is not optimal while constantly evolving technology such as Virtual Reality (VR). VR can reduce symptoms in schizophrenia with the ability to create interactive behavior and stored in the brain in order to cause hallucinations. The objective of this study was to review the benefit of VR as a hallucination therapy in schizophrenia patients. This research used a systematic literature review from five databases Nature, Frontiers, BMC, Science Direct, NEJM, and resulted in the retrieval of 55 papers. The majority of a result found a 63% review in Virtual Reality therapy can reduce hallucination in schizophrenia. VR is a technology browser and manipulator sensory environment in real-time 3D. The progressing benefit of VR verified in the treatment of schizophrenia, PSTD, anxiety, acrophobia, body image disorder, claustrophobia, and others. Some studies of schizophrenia declare that virtual reality therapy is effective in treating delusions, hallucinations, and a symptom of schizoid behavior. VR also has benefits in cognitive rehabilitation in adults or children with autism's inability and self-reliance. VR has a bright future as the treatment of mental health. The progressing of technology and research has an excellent opportunity for VR to reduce schizophrenia. Moreover, there is psychological therapy, such as cognitive-behavioral therapy and interpersonal psychotherapy. Therefore a combination needed of virtual therapy with the complementary therapy for reducing hallucination in schizophrenia.

scholarly journals Cardiovascular Diseases and COVID-19 Mortality and Intensive Care Unit Admission: A Systematic Review and Meta-analysis

2020 ◽  
Author(s):  
Amir Shamshirian ◽  
Keyvan Heydari ◽  
Reza Alizadeh-Navaei ◽  
Mahmood Moosazadeh ◽  
Saeed Abrotan ◽  
...  
Keyword(s):  
Heart Failure ◽  
Systematic Review ◽  
Cardiovascular Disease ◽  
Intensive Care Unit ◽  
Intensive Care ◽  
Cardiovascular Diseases ◽  
Meta Analysis ◽  
Cardiac Injury ◽  
Icu Admission ◽  
The World

AbstractImportanceOn 11th March, the World Health Organization declared a pandemic of COVID-19. There are over 1 million cases around the world with this disease and it continues to raise. Studies on COVID-19 patients have reported high rate of cardiovascular disease (CVD) among them and patients with CVD had higher mortality rate.ObjectivesSince there were controversies between different studies about CVD burden in COVID-19 patients, we aimed to study cardiovascular disease burden among COVID-19 patients using a systematic review and meta-analysis.Data SourcesWe have systematically searched databases including PubMed, Embase, Cochrane Library, Scopus, Web of Science as well as medRxiv pre-print database. Hand searched was also conducted in journal websites and Google Scholar.Study SelectionStudies reported cardiovascular disease among hospitalized adult COVID-19 patients with mortality or ICU admission (primary outcomes) were included into meta-analysis. In addition, all of studies which reported any cardiovascular implication were included for descriptive meta-analysis. Cohort studies, case-control, cross-sectional, case-cohort and case series studies included into the study. Finally, 16 studies met the inclusion criteria for primary outcome and 59 studies for descriptive outcome.Data Extraction and SynthesisTwo investigators have independently evaluated quality of publications and extracted data from included papers. In case of disagreement a supervisor solved the issue and made the final decision. Quality assessment of studies was done using Newcastle-Ottawa Scale tool. Heterogeneity was assessed using I-squared test and in case of high heterogeneity (>%50) random effect model was used.Main Outcomes and MeasuresMeta-analyses were carried out for Odds Ratio (OR) of mortality and Intensive Care Unit (ICU) admission for different CVDs and Standardized Mean Difference (SMD) was calculated for Cardiac Troponin I. We have also performed a descriptive meta-analysis on different CVDs.ResultsSixteen papers including 3473 patients entered into meta-analysis for ICU admission and mortality outcome and fifty-nine papers including 9509 patients for descriptive outcomes. Results of meta-analysis indicated that acute cardiac injury, (OR: 15.94, 95% CI 2.31-110.14), hypertension (OR: 1.92, 95% CI 1.92-2.74), heart Failure (OR: 11.73, 95% CI 5.17-26.60), other cardiovascular disease (OR: 1.95, 95% CI 1.17-3.24) and overall CVDs (OR: 3.37, 95% CI 2.06-5.52) were significantly associated with mortality in COVID-19 patients. Arrhythmia (OR: 22.17, 95%CI 4.47-110.04), acute cardiac injury (OR: 19.83, 95%CI 7.85-50.13), coronary heart disease (OR: 4.19, 95%CI 1.27-13.80), cardiovascular disease (OR: 4.17, 95%CI 2.52-6.88) and hypertension (OR: 2.69, 95%CI 1.55-4.67) were also significantly associated with ICU admission in COVID-19 patients.ConclusionOur findings showed a high burden of CVDs among COVID-19 patients which was significantly associated with mortality and ICU admission. Proper management of CVD patients with COVID-19 and monitoring COVID-19 patients for acute cardiac conditions is highly recommended to prevent mortality and critical situations.Key PointsQuestionAre cardiovascular disease associated with mortality and Intensive Care Unit admission (ICU) of COVID-19 patients?FindingsIn this systematic review and meta-analysis, acute cardiac injury, hypertension, heart failure and overall cardiovascular diseases were significantly associated with mortality in COVID-19 patients. Arrhythmia, coronary heart disease, hypertension, acute cardiac injury and other cardiovascular disease were significantly associated with ICU admission of COVID-19 patients.MeaningCardiovascular diseases have significant role in mortality and disease severity of COVID-19 patients. COVID-19 patients need to be carefully monitored for cardiovascular diseases and managed properly in case of acute cardiac conditions.

scholarly journals A review of post infectious pulmonary fibrosis in the era of COVID-19 and potential treatment options

2021 ◽  
Vol 9 (40) ◽  
pp. 37-46
Author(s):  
Medha Ghose ◽  
Maehali Patel
Keyword(s):  
Risk Factors ◽  
Pulmonary Fibrosis ◽  
Treatment Options ◽  
World Health ◽  
Potential Treatment ◽  
Pulmonary Injury ◽  
The World ◽  
Health Organization ◽  
Post Infectious

On March 11, 2020, the World Health Organization (WHO) released a statement characterizing COVID-19 as a pandemic that has, as of October 2020, caused almost 36 million confirmed global cases and over 1 million deaths. One of the long-term complications suggested by researchers is fibrosis. It has been hypothesized that the combination of ongoing pulmonary injury caused by COVID-19 and the inability to promptly repair damage results in interstitial matrix widening and eventual compression and destruction of alveoli and capillaries. Here we focus on pathogenesis, risk factors, different infectious causes of fibrosis along with COVID-19, and potential treatment options that might reduce its effects. Key words: COVID-19, pulmonary fibrosis, mechanism, treatment

scholarly journals The efficacy and safety of interferons for the treatment of patients with COVID-19: protocol for systematic review and meta-analysis of controlled trials

2021 ◽  
Author(s):  
Afsaneh Noormandi ◽  
Mohammad Fathalipour ◽  
Reza Daryabeygi-Khotbehsara ◽  
Soheil Hassanipour
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Meta Analysis ◽  
World Health ◽  
Controlled Trials ◽  
Efficacy And Safety ◽  
Global Pandemic ◽  
The World ◽  
Health Organization ◽  
Time Of Administration

Background and objective: COVID-19 has since been declared a global pandemic by the World Health Organization (WHO), infecting millions worldwide. The use of Interferon (INF) subtypes previously examined in the treatment of SARS and MERS is also being initiated in some clinical trials. Although different clinical trials were evaluated IFNs in the treatment of COVID-19, their efficacy and safety remain unknown. Therefore, this study aims to systematically assess IFNs efficacy and safety in treating patients with COVID-19. Methods: The protocol has been registered in the PROSPERO International Prospective Register (CRD42020200643) on 24 July 2020. This protocol has been arranged according to the PRISMA-P (Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols) 2015 checklist. Discussion: Due to lack of approved medication for the covid-19 treatment and also various mutations of this virus, evaluated the efficacy and safety of medications by various studies could help for finding treatments with high effectiveness. IFNs are one of the medications that have been administered in covid-19 infection.  Moreover, the best time of administration and dose of this medication was unknown. Although meta-analysis is a potent source for assessing the accuracy of subjects, heterogeneity of articles is a potent limitation of our work.

Sign in / Sign up

Export Citation Format

Share Document